FDA Approves Yosprala (aspirin and omeprazole) for Secondary Prevention of Cardiovascular Disease in Patients at Risk for Aspirin-Associated Gastric Ulcers
MISSISSAUGA, Ontario, Sept. 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved once-daily Yosprala,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Aspirin | Cardiology | Cardiovascular | Drugs & Pharmacology | Food and Drug Administration (FDA) | Gastric Ulcer | Gastroenterology | Heart | Omeprazole | Prilosec